This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig. Another purpose is to check whether the combination study treatment can make tumours shrink. Obrixtamig and pumitamig are being developed to help the immune system fight cancer. Participants are put into 2 groups. One group gets obrixtamig and pumitamig. The other group gets obrixtamig and pumitamig with standard chemotherapy (carboplatin and etoposide). All study treatments are given as infusions into a vein. This study does not have a fixed duration. Participants can receive obrixtamig and pumitamig for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.
Original English text from ClinicalTrials.gov
✓ Qualifies
✗ Disqualifies
Simplified criteria — AI translation
Stanford University
San Francisco, United States
University Of Colorado
Aurora, United States
Florida Cancer Specialists - Sarasota
Sarasota, United States
Winship Cancer Institute
Atlanta, United States
Dana Farber Cancer Institute
Boston, United States
Washington University Medical Center, Division of Oncology
St Louis, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
The West Clinic - Memphis (Union Ave)
Germantown, United States
SCRI Oncology Partners
Nashville, United States
IDS (IDS) Pharmacist South Texas Accelerated Resear Therapeutics, LLC START
San Antonio, United States
Kinghorn Cancer Centre
Darlinghurst, Australia
Monash Health Monash Medical Centre
Clayton, Australia
Linear Clinical Research Ltd
Nedlands, Australia
UZ Antwerpen
Edegem, Belgium
CHU de Liège
Herstal, Belgium
GasthuisZusters Antwerpen
Wilrijk, Belgium
British Columbia Cancer Agency
Vancouver, Canada
Ottawa Hospital Regional Cancer Centre
Ottawa, Canada
Princess Margaret Cancer Centre
Toronto, Canada
Sir Mortimer B Davis Jewish General Hospital
Montreal, Canada
University General Hospital ''ATTIKON'' - General Hospital of West Attica H AGIA VARVARA
Chaïdári, Greece
Sotiria Thoracic Diseases Hospital of Athens
Athens, Greece
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Netherlands
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center - PPDS
Seoul, South Korea
Samsung Medical Center - PPDS
Seoul, South Korea
Severance Hospital Yonsei University Health System - Clinical Trials Center Pharmacy
Seoul, South Korea
ICO l?Hospitalet ? Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, Spain
START MADRID_Hospital Universiario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 De Octubre
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Karolinska Universitetssjukhuset Solna
Stokholm, Solna, Sweden
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.
We use Google Analytics to understand how you use our tools and to improve them. We don't collect health data and we don't show ads. You can decline - the site will work exactly the same. Privacy policy